Malignant Gliomas as Second Neoplasms in Pediatric Cancer Survivors: Neuropathological Study

Figure 4

Molecular findings assessed immunohistochemically: (a) strong nuclear PTEN reactivity (P1, PTEN, 200x), (b) strong PI3K expression (P5rec, PI3K, 200x), (c) cytoplasmic/nuclear pAKT immunoreactivity (P1, pAKT, 400x) (d) p-mTOR cytoplasmic/nuclear expression within the neoplastic cells (P5rec, p-mTOR, 200x), (e) nuclear p53 staining within 60% of glioma cells (P2, p53, 200x), (f) moderate cytoplasmic/membranous EGFR expression (P3, EGFR, 400x), (g) strong cytoplasmic HER3 reactivity (P1, HER3, 400x), (h) high level MGMT staining (P3, MGMT, 200x).

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)